Mobius Therapeutics, LLC

Mobius Therapeutics, LLC is a biotechnology startup established in 2006, based in the United States. The company's flagship product, Mitosol, gained FDA approval in 2012 and has since been recognized as the standard for mitomycin-c preparation and delivery in ophthalmic operating rooms. The company's approach extends beyond addressing current challenges, aiming to optimize products for use in the ophthalmic operating room and obtain regulatory approval to provide FDA-approved and cGMP-compliant products. One notable aspect of Mobius Therapeutics is its commitment to addressing the frustrations associated with ophthalmic perioperative injectables, which are often off-label, inconveniently compounded, and packaged in multi-dose vials. The company is focused on designing products that meet the stringent requirements of the ophthalmic operating room environment. In terms of investment, the company secured a significant $5.00M Series B investment from Cultivation Capital on 10 October 2013. Looking ahead, Mobius Therapeutics is not limited to its current product portfolio and is actively pursuing the development and regulatory submission of additional products. The company seeks to collaborate closely with the ophthalmic community, indicating a promising trajectory for future growth and innovation in the biotechnology sector.